First Marketing Authorization secured by Venus Remedies for Plerixafor in any market Advances the company's shift into higher value specialty injectables across regulated markets Plerixafor is a stem cell mobilization therapy used in autologous transplantation for multiple myeloma and non-Hodgkin lymphoma Venus Remedies Limited (NSE:
Approval marks Venus Remedies’ entry into Argentina for Ceftriaxone, taking total global MAs for the antibiotic to 39 Argentina is the 4th-largest pharmaceutical market in Latin America, valued at approximately US$7.3 billion in 2023 Approval strengthens Venus Remedies’ growing international anti infective portfolio amid rising burden of infectious
The latest disbursement underscores the Company’s role in strengthening India’s domestic pharmaceutical manufacturing ecosystem Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the world’s leading fixed-dosage injectable manufacturers, has received its second incentive disbursement under the Government of India’s Production Linked Incentive (PLI) Scheme for Pharmaceuticals, representing 75 percent
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the world’s leading fixed-dosage injectable manufacturers, has secured the marketing authorization from the Indonesian regulatory authority
The approvals strengthen India’s position as a reliable supplier of advanced pharmaceuticals across ASEAN markets where Venus Remedies already exports more than 374 products. Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the 10 leading fixed-dosage injectable manufacturers in the world, has secured new marketing authorizations
VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, uniquely developed to mitigate the nephrotoxic effects associated with conventional polymyxin B (PMB) therapy Key preclinical findings for VRP-034 included up to 70% reduction in nephrotoxicity compared to marketed PMB The QIDP
Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading research-driven global pharmaceutical company, has joined the United Nations Global Compact (UNGC), the world’s largest corporate sustainability initiative. With this strategic move, the company aligns its operations and strategies with the UNGC’s Ten Principles on human rights, labour,
AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, today announces that it has entered into a research collaboration agreement with Venus Remedies Limited (India). Venus Remedies Limited will perform a pre-clinical evaluation of AdjuTec Pharma´s APC-148 platform technology. AdjuTec Pharma has developed novel
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations With its debut registration of Sugammadex in Philippines, Venus Remedies strengthens its foothold in the ASEAN market Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading Indian manufacturer
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies and could be game-changing for patients suffering from Gram-negative, MBL-resistant infections Meropenem resistance in India is as high as 62-87%, with up to 50% linked to MBL prevalence, according to ICMR
